Ke Zhangmin, Shen Kaikai, Wang Li, Xu Hao, Pan Xia, Qian Zhenjue, Wen Yuting, Lv Tangfeng, Zhang Xiuwei, Song Yong
Department of Respiratory and Critical Care Medicine, Affiliated Jiangning Hospital of Nanjing Medicine University, Nanjing, China.
Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China.
Front Immunol. 2025 Jan 29;16:1531246. doi: 10.3389/fimmu.2025.1531246. eCollection 2025.
Succinylation represents an emerging class of post-translational modifications (PTMs), characterized by the enzymatic or non-enzymatic transfer of a negatively charged four-carbon succinyl group to the ϵ-amino group of lysine residues, mediated by succinyl-coenzyme A. Recent studies have highlighted the involvement of succinylation in various diseases, particularly cancer progression. Sirtuin 5 (SIRT5), a member of the sirtuin family, has been extensively studied for its robust desuccinylase activity, alongside its deacetylase function. To date, only a limited number of SIRT5 substrates have been identified. These substrates mediate diverse physiological processes such as glucose oxidation, fatty acid oxidation, ammonia detoxification, reactive oxygen species scavenging, anti-apoptosis, and inflammatory responses. The regulation of these activities can occur through either the same enzymatic activity acting on different substrates or distinct enzymatic activities targeting the same substrate. Aberrant expression of SIRT5 has been closely linked to tumorigenesis and disease progression; however, its role remains controversial. SIRT5 exhibits dual functionalities: it can promote tumor proliferation, metastasis, drug resistance, and metabolic reprogramming, thereby acting as an oncogene; conversely, it can also inhibit tumor cell growth and induce apoptosis, functioning as a tumor suppressor gene. This review aims to provide a comprehensive overview of the current research status of SIRT5. We discuss its structural characteristics and regulatory mechanisms, compare its functions with other sirtuin family members, and elucidate the mechanisms regulating SIRT5 activity. Specifically, we focus on the role of succinylation modification mediated by SIRT5 in tumor progression, highlighting how desuccinylation by SIRT5 modulates tumor development and delineating the underlying mechanisms involved.
琥珀酰化是一类新兴的翻译后修饰(PTM),其特征是在琥珀酰辅酶A的介导下,带负电荷的四碳琥珀酰基团通过酶促或非酶促方式转移到赖氨酸残基的ε-氨基上。最近的研究强调了琥珀酰化在各种疾病,特别是癌症进展中的作用。沉默调节蛋白5(SIRT5)是沉默调节蛋白家族的成员,因其强大的去琥珀酰化酶活性以及脱乙酰酶功能而受到广泛研究。迄今为止,仅鉴定出有限数量的SIRT5底物。这些底物介导多种生理过程,如葡萄糖氧化、脂肪酸氧化、氨解毒、活性氧清除、抗凋亡和炎症反应。这些活性的调节可以通过作用于不同底物的相同酶活性或靶向相同底物的不同酶活性来实现。SIRT5的异常表达与肿瘤发生和疾病进展密切相关;然而,其作用仍存在争议。SIRT5具有双重功能:它可以促进肿瘤增殖、转移、耐药和代谢重编程,从而起到癌基因的作用;相反,它也可以抑制肿瘤细胞生长并诱导凋亡,发挥肿瘤抑制基因的功能。本综述旨在全面概述SIRT5的当前研究现状。我们讨论其结构特征和调节机制,将其功能与其他沉默调节蛋白家族成员进行比较,并阐明调节SIRT5活性的机制。具体而言,我们重点关注SIRT5介导的琥珀酰化修饰在肿瘤进展中的作用,强调SIRT5的去琥珀酰化如何调节肿瘤发展并描绘其中涉及的潜在机制。